|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
762.73 USD |
-2.84% | -6.91% | -1.20% | |
Published on 06/22/2025 at 06:00
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Eli Lilly’s Orforglipron Reduces Blood Sugar, Weight in Phase 3 Trial |
06:00am |
MT |
|
China’s Sciwind’s GLP-1 shows similar weight loss to Novo’s Wegovy, study finds |
Jun. 21 |
RE |
|
Lilly expects orforglipron obesity results in third quarter |
Jun. 21 |
RE |
|
Eli Lilly and Company Announces Detailed Results from ACHIEVE-1, a Phase 3 Trial Evaluating the Safety and Efficacy of Orforglipron Compared to Placebo in Adults with Type 2 Diabetes and Inadequate Glycemic Control with Diet and Exercise Alone |
Jun. 21 |
CI |
|
S&P 500 Edges Down Weekly as Declines Led by Health Care Outweigh Energy-Led Gains |
Jun. 20 |
MT |
|
Sector Update: Health Care Stocks Retreat Late Afternoon |
Jun. 20 |
MT |
|
Sector Update: Health Care Stocks Softer in Afternoon Trading |
Jun. 20 |
MT |
|
Sector Update: Health Care |
Jun. 20 |
MT |
|
Lilly to Appeal Against UK Regulator’s Recommendation Not to Reimburse Cost of Alzheimer’s Drug |
Jun. 20 |
MT |
|
US judge upholds FDA’s removal of Ozempic, Wegovy from drug shortage list |
Jun. 20 |
RE |
|
Lilly to Appeal Against UK Regulator’s Recommendation Not to Reimburse Cost of Alzheimer’s Drug |
Jun. 20 |
MT |
|
Lilly to Appeal Against UK Regulator’s Recommendation Not to Reimburse Cost of Alzheimer’s Drug |
Jun. 20 |
MT |
|
Eli Lilly Says Indian Market’s Response to Weight-Loss Drug Mounjaro is ‘Positive’ |
Jun. 20 |
MT |
|
EMA’s CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment |
Jun. 20 |
RE |
|
Eli Lilly says India response to obesity drug Mounjaro is ‘positive’, will focus on meeting demand |
Jun. 20 |
RE |
|
Obesity: preserving muscle, the new challenge |
Jun. 19 |
 |
|
Rybodyn Selects to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome |
Jun. 19 |
CI |
|
Eli Lilly to Appeal UK Reimbursement Decision for Alzheimer’s Treatment |
Jun. 18 |
MT |
|
Lilly to appeal after UK agency opposes reimbursement for Alzheimer’s drug |
Jun. 18 |
RE |
|
S&P 500 ends nearly flat, gives back gains; Fed’s Powell says inflation to rise |
Jun. 18 |
RE |
|
S&P 500 ends nearly flat, gives back gains; Fed’s Powell says inflation to rise |
Jun. 18 |
RE |
|
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough |
Jun. 18 |
RE |
|
Deals of the day-Mergers and acquisitions |
Jun. 18 |
RE |
|
S&P 500 ends near flat, gives back gains after Fed’s Powell speaks |
Jun. 18 |
RE |
|
Indexes briefly add to gains after Fed statement, trade volatile |
Jun. 18 |
RE |
LLY: Dynamic Chart
Eli Lilly and Company is one of the world’s leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
– endocrinology (65.5%): products for treating osteoporosis, diabetes, and growth problems;
– oncology (19.4%);
– immunology diseases (9.8%);
– neurology (3.3%): primarily drugs used in treating depression and schizophrenia;
– other (2%).
Net sales are distributed geographically as follows: the United States (67.4%), Europe (15.4%), Japan (4%), China (3.7%) and other (9.5%).
More about the company
Buy
Last Close Price
762.73USD
Average target price
951.98USD
Spread / Average Target
+24.81%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
